View clinical trials related to Substance-Related Disorders.
Filter by:The prevalence of asthma among athletes is higher than in the normal population and endurance athletes are especially at increased risk. The gold standard for asthma treatment is inhaled glucocorticoids with inhaled beta2 agonists before exercise and as a symptom relief. However, the use of beta2 agonists in sports is debated because of potential performance-enhancing effects and its use is regulated by the World Anti-Doping Agency (WADA). The potential performance-enhancing effect of beta2 agonists on endurance performance and sprint performance has each been investigated in several studies as it has been suspected that non-asthmatic athletes use beta2 agonists for the purpose of improving performance. In conclusion, beta2 agonists do not improve endurance athletic performance in the doses and methods of use permitted by WADA. When it comes to anaerobic performance, the evidence is currently non-conclusive as studies report conflicting effects. It is therefore conceivable that beta2 agonists can improve the ability to sprint and increase power output during short periods of high energy expenditure during an endurance competition. By testing such anaerobic skills during endurance work in athletes, this study will provide valuable knowledge about whether this drug may affect sports performance and will be of interest to WADA and anyone else interested in fair play in sports. The purpose of the project is to investigate whether the use of a WADA approved dose of salbutamol (albuterol/Ventoline) has a performance-enhancing effect on sprint performance during and after endurance work on an ergometer bike. Well-trained cyclists who do not have asthma will perform two identical cycling protocols on two different days. The study is designed as a double-blind cross-over study with placebo. Participants will perform multiple 30-second sprints during a standard submaximal effort to investigate the effect of salbutamol on the maximum and average power of these sprints.
Family Talk, an evidence-based parent-youth dyadic intervention, is a promising approach to improving substance use outcomes for high-risk families, and its structure lends itself to delivery by existing personnel within an Office-Based Addiction Treatment (OBAT) model of care. The investigators propose a single-arm pilot study with 25 parent-youth dyads through which a rapid cycle performance improvement approach will be employed to adapt and optimize the content and delivery of the embedded Family Talk prevention strategy. The investigators will field-test relevant baseline and outcome measures and will use qualitative methodology to identify key modifications to the intervention and generate hypotheses for how the prevention strategy may impact youth and family outcomes and prevent youth substance use. Information from this study will inform a subsequent pilot randomized controlled trial of the intervention to prevent substance use for youth whose parents are in recovery from SUD (substance use disorder).
The study is exploring the ease and ability to integrate a mobile application in outpatient behavioral health treatment. There are two major aims to the study: 1) Determine feasibility and acceptability of integrating a mobile app into behavioral health treatment for adolescents with co-occurring substance use and mental health disorders, and 2) identify initial signal of effect on engagement and/or treatment outcomes among youth who use the mobile app.
The study aims to examine the effect of buprenorphine on suicidal ideation in individuals with opioid use disorder, and to investigate the functional brain activity related to its potential anti-suicidal effect.
The purpose of this study is to evaluate the impact of a manualized in-hospital recovery coach intervention on rates of post-discharge treatment retention and alcohol use among hospitalized patients with alcohol use disorder.
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy. Patients will be randomized to two arms: (1) ANS-6637 for three months vs (2) Placebo for three months. Subjects will subsequently be followed for an additional one month post treatment.
Examine the feasibility and acceptability of delivering the S4E intervention to 20 African-American youths between the ages 16-21 in Flint, Michigan. The investigators will examine the preliminary efficacy of the S4E intervention in improving the uptake of HIV self-testing immediately post-intervention.
People who inject drugs (PWID) experience high risk of HIV acquisition. Antiretroviral pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention strategy for high risk HIV-uninfected individuals including PWID, yet uptake has been low in this population and uptake and adherence interventions have not been developed or tested. Drawing from formative qualitative research, the overall goal of this project is to develop an intervention to promote PrEP uptake and adherence among PWID in the U.S. Northeast. The investigators will: - Analyze existing literature and data to identify specific barriers and facilitators to PrEP uptake and adherence among PWID to inform the initial adaptation of existing theory-based interventions; - Conduct qualitative interviews with ~30 PWID and ~10 key informants (PrEP and other clinical and social service providers) to identify intervention targets; - Develop and iteratively refine and finalize an intervention manual based on feedback from qualitative exit-interviews with an interventionist and ~10 PWID; and - Conduct a pilot randomized clinical trial (RCT) in ~50 HIV-uninfected PWID to compare PrEP uptake and adherence outcomes and assess intervention feasibility and acceptability.
This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.
This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings. This is a randomized controlled trial to a cohort of pregnant women seeking medication-assisted treatment for opioid use disorders. Half of participants will receive buprenorphine, while the other half of participants receive a combination of buprenorphine/naloxone